Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-445 combination therapy in cystic fibrosis patients homozygous for F508del (F/F)
2018-000184-89Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of elexacaftor in cystic fibrosis (CF) (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Absolute change in ppFEV1 from baseline at Week 4. Started Jul 2018; status: completed.
02
Drugs
elexacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2018-000184-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000184-89.